The recent US approval of a new low dose of colchicine 0.5 mg (Lodoco; Agepha Pharma) with a broad indication for use in atherosclerotic cardiovascular disease (ASCVD) represents a completely new ...

An exploratory analysis of the LoDoCo2 (Low-Dose Colchicine 2) randomized, controlled, double-blind trial found that daily therapy with a low dose of colchicine was associated with lower incidences of ...

The LoDoCo2 trial found a reduced cardiovascular risk with low-dose colchicine in patients with chronic coronary disease. In this substudy, attenuation of pericoronary adipose tissue did not differ ...

BASEL, Switzerland—Low-dose colchicine doesn’t significantly reduce MACE in patients who have had a nonsevere ischemic stroke or high-risk TIA, according to the results of the CONVINCE trial. Through ...

(UPDATED) Colchicine taken at a daily dose of 0.5 mg safely reduces cardiovascular events among patients with chronic coronary disease, according to data from the placebo-controlled randomized LoDoCo2 ...

Colchicine may be used with caution to manage flare-ups of crystal-induced arthritis among patients with severe chronic kidney disease, with dosage modifications and careful monitoring required.

An Australian-Dutch trial led by Perth GenesisCare cardiologists, Professor Peter Thompson and Dr Mark Nidorf, in collaboration with the Dutch Network for Cardiovascular Research (WCN) in the ...

Please provide your email address to receive an email when new articles are posted on . In patients with chronic coronary disease, adding low-dose colchicine to optimal medical therapy reduced risk ...

Taking low-dose colchicine daily may slow the progression of a common acquired gene mutation found in the blood of older adults that can lead to certain blood cancers and increased risk of ...

The open-label, prospective study (GRECCO-19) assessed the effect of treatment with low-dose colchicine on cardiac and inflammatory biomarkers as well as clinical outcomes. Colchicine could ...

Please provide your email address to receive an email when new articles are posted on . Benefits of low-dose colchicine were consistent in men over a median follow-up period of 28.6 months. Due to low ...